Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LUCAR-20S
- Development stage
- Phase 1
- Lead developer
- Legend Biotech
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
LUCAR-20S is an allogeneic chimeric antigen receptor (CAR) T cell therapy engineered to target the CD20 antigen, which is expressed on the surface of B cells. Upon administration, these donor-derived CAR-T cells specifically recognize and kill CD20-expressing tumor cells. The therapy is being developed for use in patients with relapsed or refractory (R/R) CD20-positive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma. As an "off-the-shelf" allogeneic product, it offers potential advantages over autologous CAR-T therapies by enabling immediate availability without the need for patient-specific manufacturing[1][2][3][7].
- Brand names
- LUCAR-20SLUCAR20SLUCAR 20S
- Other names
- allogeneic anti-CD20 CAR T cells LUCAR-20S
02
Targets
Beyond the preview
Go deeper on LUCAR-20S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LUCAR-20S.